MilliporeSigma Articles

  1. Streamline Your AAV Process With A Production Platform 10/6/2025

    AAVs are reshaping gene therapy, but scaling production introduces complexity. Learn how upstream process optimization can improve yield, consistency, and speed to meet growing demands.

  2. Achieve Higher Targeted Concentrations 9/30/2025

    Single-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.

  3. Cell Culture Media Fingerprinting 9/8/2025

    Ensure consistency and quality in production with an advanced CCM fingerprinting technique that is capable of identifying over 100 media components to reduce variability and meet regulatory standards.

  4. How To Fingerprint Cell Culture Media 9/8/2025

    Ensuring media identity and consistency is vital in biologics manufacturing. Discover why quantifying cell culture media components before batch release helps overcome formulation complexity.

  5. Elevating mRNA Manufacturing Toward GMP-Readiness 8/27/2025

    The mRNA Technology Transfer Program empowers LMICs with scalable vaccine production. Learn about a partnership that drives innovation in mRNA and sets a global blueprint for equitable health access.

  6. Stabilization Of RNA-Loaded Lipid Nanoparticles By Lyophilization 8/15/2025

    Discover how lyophilization enhances RNA-based therapeutics by enabling storage at higher temperatures, which simplifies cold-chain logistics while preserving nanoparticle integrity and biological activity.

  7. Perfusion Cell Line Development For Intensified Processes 5/5/2025

    The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.

  8. De-Mystifying Regulatory Support During Viral Vector-Based Development 4/15/2025

    Navigating clinical trials for viral vector-based cell and gene therapies demands specialized expertise and regulatory insight. Learn how scientific acumen and strategic planning bring innovative therapies from lab to patient.

  9. Navigating Next-Generation Quality Control Strategies For AAV Testing 3/10/2025

    AAV-based gene therapies, while promising, require rigorous quality control through advanced methodologies to ensure safety, efficacy, and regulatory compliance.

  10. Key Regulatory Considerations For The Next Wave Of Gene Therapies 2/21/2025

    The evolving field of viral vector production, driven by advances in gene and cell therapies, is facing increasing regulatory scrutiny and analytical demands.